# Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)

> **NCT00876772** · PHASE2,PHASE3 · COMPLETED · sponsor: **Charite University, Berlin, Germany** · enrollment: 40 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** Olanzapine

## Key facts

- **NCT ID:** NCT00876772
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00876772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00876772, "Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT00876772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*